HIV Injection Market By Distribution Channel (Hospital Pharmacy, Drugs Stores and Retail Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

List of Tables

The HIV injection market was valued at $1 billion in 2023 and is estimated to reach $5.5 billion by 2033, exhibiting a CAGR of 17.9% from 2024 to 2033. Human immunodeficiency virus (HIV) is a virus that attacks the immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections. HIV is primarily transmitted through unprotected sexual intercourse, sharing of contaminated needles, and from an infected mother to her baby during childbirth or breastfeeding. Advances in antiretroviral therapy (ART) have significantly improved the prognosis for people living with HIV, helping to control the virus, prevent the progression to AIDS, and enhance overall quality of life. Regular testing, early detection, and access to medical care are crucial in managing and preventing the spread of HIV.

Public awareness, education, and ongoing research remain essential in the global effort to combat this infectious disease. HIV injections are designed to deliver antiretroviral drugs directly into the bloodstream, ensuring effective and consistent levels of the medication in the body. These injections can come in various forms, including intramuscular injections (administered into the muscle) or subcutaneous injections (administered just beneath the skin). The HIV injection market is driven by rise in the number of people suffering from HIV, development and introduction of novel antiretroviral drugs in injectable formulations, rise in demand for long acting and extended delivery HIV prevention and treatment regimens, rise in investment in R and D activities, and growing government initiatives and healthcare policies for HIV.

For instance, according to the Joint United Nations Program on HIV and AIDS (UNAIDS), 39 million people globally were living with HIV in 2022. Thus, rise in the number of HIV cases increases the demand for HIV injections and drives the growth of market. In addition, ongoing R and D efforts in the field of HIV treatment led to continuous advancements which is expected to drive the market growth. The introduction of novel antiretroviral drugs, particularly those in injectable formulations, provides healthcare providers and patients with more options for managing the virus, thereby driving market growth. For instance, GlaxoSmithKline plc company manufactured combination of cabotegravir and rilpivirine, a long-acting injectable antiretroviral drug for the treatment of HIV. This regimen, known as Cabenuva (Vocabria and Rekambys in Europe), involves the intramuscular injection of cabotegravir, an integrase inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor. This long-acting injectable regimen has been approved in several high-income countries and has shown promise in maintaining viral suppression.

Furthermore, the government initiatives and healthcare policies, aimed at expanding access to HIV treatment and improving healthcare infrastructure, play a pivotal role, which is expected to drive the market growth. For instance, Ending the HIV Epidemic (EHE) initiative, coordinated by the U.S. Department of Health and Human Services (HHS) aims to reduce the number of new HIV infections in the U.S. by 75% by 2025 and then by at least 90% by 2030. It focuses on leveraging scientific advances in HIV prevention, diagnosis, treatment, and outbreak response to address racial, ethnic, and geographic disparities.

However, the stringent regulatory process for approval and lack of education about HIV prevention in underdeveloped countries are factors responsible for impeding the growth of the HIV injection market. In contrast, rise in number of pipeline drugs for HIV and high growth potential in emerging countries provides lucrative opportunity to the market growth. For instance, in June 2021, ImmunityBio, Inc., a clinical-stage immunotherapy company, announced its HIV clinical pipeline with an HIV cure study using Anktiva (N-803), which is now enrolling participants in the U.S. The trial is expected to study whether Anktiva can control HIV alone or together with combination broadly neutralizing antibodies (bNABs) after participants stop their antiretroviral therapy (ART) and they are carefully monitored.

The HIV injection market is segmented on the basis of distribution channel and region. By distribution channel, the market is classified into hospital pharmacy, drug stores and retail pharmacy, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global HIV injection market are GlaxoSmithKline plc, Johnson and Johnson, Gilead Sciences, Inc., ImmunityBio, Inc., F. Hoffmann-La Roche Ltd, Theratechnologies Inc., Viriom, Inc., Shionogi & Co., Ltd., AbbVie Inc., and Brii Biosciences. Key players operating in the market have adopted product approvals, partnership, expansion, agreement, and clinical trial as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv injection market analysis from 2023 to 2033 to identify the prevailing hiv injection market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hiv injection market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hiv injection market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Distribution Channel

Others
Hospital Pharmacy
Drugs Stores and Retail Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

GlaxoSmithKline plc
Johnson & Johnson
Gilead Sciences, Inc.
F. Hoffmann-La Roche Ltd.
AbbVie Inc.
Shionogi & Co., Ltd.
ImmunityBio, Inc.
Theratechnologies Inc.
Viriom, Inc.
Brii Biosciences

Product Code: A312373

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in number of people receiving HIV therapy
  - 3.4.1.2. Growing awareness & initiatives taken by government for HIV
  - 3.4.1.3. Rise in number of product approvals
- 3.4.2. Restraints
  - 3.4.2.1. Stringent regulatory processes for the approval
- 3.4.3. Opportunities
  - 3.4.3.1. High growth potential in emerging markets
  - 3.4.3.2. Rise in number of pipeline products

CHAPTER 4: HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Hospital Pharmacy
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Drugs Stores and Retail Pharmacies
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: HIV INJECTION MARKET, BY REGION

5.1. Overview
- 5.1.1. Market size and forecast By Region
5.2. North America
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by Distribution Channel
- 5.2.3. Market size and forecast, by country
  - 5.2.3.1. U.S.
  - 5.2.3.1.1. Market size and forecast, by Distribution Channel
  - 5.2.3.2. Canada
  - 5.2.3.2.1. Market size and forecast, by Distribution Channel
  - 5.2.3.3. Mexico
  - 5.2.3.3.1. Market size and forecast, by Distribution Channel
5.3. Europe
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by Distribution Channel
- 5.3.3. Market size and forecast, by country
  - 5.3.3.1. Germany
  - 5.3.3.1.1. Market size and forecast, by Distribution Channel
  - 5.3.3.2. France
  - 5.3.3.2.1. Market size and forecast, by Distribution Channel
  - 5.3.3.3. UK
  - 5.3.3.3.1. Market size and forecast, by Distribution Channel
  - 5.3.3.4. Italy
  - 5.3.3.4.1. Market size and forecast, by Distribution Channel
  - 5.3.3.5. Spain
  - 5.3.3.5.1. Market size and forecast, by Distribution Channel
  - 5.3.3.6. Rest of Europe
  - 5.3.3.6.1. Market size and forecast, by Distribution Channel
5.4. Asia-Pacific
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by Distribution Channel
- 5.4.3. Market size and forecast, by country
  - 5.4.3.1. Japan
  - 5.4.3.1.1. Market size and forecast, by Distribution Channel
  - 5.4.3.2. China
  - 5.4.3.2.1. Market size and forecast, by Distribution Channel
  - 5.4.3.3. India
  - 5.4.3.3.1. Market size and forecast, by Distribution Channel
  - 5.4.3.4. Australia
  - 5.4.3.4.1. Market size and forecast, by Distribution Channel
  - 5.4.3.5. South Korea
  - 5.4.3.5.1. Market size and forecast, by Distribution Channel
  - 5.4.3.6. Rest of Asia-Pacific
  - 5.4.3.6.1. Market size and forecast, by Distribution Channel
5.5. LAMEA
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by Distribution Channel
- 5.5.3. Market size and forecast, by country
  - 5.5.3.1. Brazil
  - 5.5.3.1.1. Market size and forecast, by Distribution Channel
  - 5.5.3.2. Saudi Arabia
  - 5.5.3.2.1. Market size and forecast, by Distribution Channel
  - 5.5.3.3. South Africa
  - 5.5.3.3.1. Market size and forecast, by Distribution Channel
  - 5.5.3.4. Rest of LAMEA
  - 5.5.3.4.1. Market size and forecast, by Distribution Channel

CHAPTER 6: COMPETITIVE LANDSCAPE

6.1. Introduction
6.2. Top winning strategies
6.3. Product mapping of top 10 player
6.4. Competitive dashboard
6.5. Competitive heatmap
6.6. Top player positioning, 2023

CHAPTER 7: COMPANY PROFILES

7.1. GlaxoSmithKline plc
- 7.1.1. Company overview
- 7.1.2. Key executives
- 7.1.3. Company snapshot
- 7.1.4. Operating business segments
- 7.1.5. Product portfolio
- 7.1.6. Business performance
- 7.1.7. Key strategic moves and developments
7.2. Johnson & Johnson
- 7.2.1. Company overview
- 7.2.2. Key executives
- 7.2.3. Company snapshot
- 7.2.4. Operating business segments
- 7.2.5. Product portfolio
- 7.2.6. Business performance
- 7.2.7. Key strategic moves and developments
7.3. Gilead Sciences, Inc.
- 7.3.1. Company overview
- 7.3.2. Key executives
- 7.3.3. Company snapshot
- 7.3.4. Operating business segments
- 7.3.5. Product portfolio
- 7.3.6. Business performance
- 7.3.7. Key strategic moves and developments
7.4. ImmunityBio, Inc.
- 7.4.1. Company overview
- 7.4.2. Key executives
- 7.4.3. Company snapshot
- 7.4.4. Operating business segments
- 7.4.5. Product portfolio
- 7.4.6. Business performance
- 7.4.7. Key strategic moves and developments
7.5. F. Hoffmann-La Roche Ltd.
- 7.5.1. Company overview
- 7.5.2. Key executives
- 7.5.3. Company snapshot
- 7.5.4. Operating business segments
- 7.5.5. Product portfolio
- 7.5.6. Business performance
7.6. Theratechnologies Inc.
- 7.6.1. Company overview
- 7.6.2. Key executives
- 7.6.3. Company snapshot
- 7.6.4. Operating business segments
- 7.6.5. Product portfolio
- 7.6.6. Business performance
- 7.6.7. Key strategic moves and developments
7.7. Viriom, Inc.
- 7.7.1. Company overview
- 7.7.2. Key executives
- 7.7.3. Company snapshot
- 7.7.4. Operating business segments
- 7.7.5. Product portfolio
7.8. AbbVie Inc.
- 7.8.1. Company overview
- 7.8.2. Key executives
- 7.8.3. Company snapshot
- 7.8.4. Operating business segments
- 7.8.5. Product portfolio
- 7.8.6. Business performance
7.9. Brii Biosciences
- 7.9.1. Company overview
- 7.9.2. Key executives
- 7.9.3. Company snapshot
- 7.9.4. Operating business segments
- 7.9.5. Product portfolio
- 7.9.6. Business performance
7.10. Shionogi & Co., Ltd.
- 7.10.1. Company overview
- 7.10.2. Key executives
- 7.10.3. Company snapshot
- 7.10.4. Operating business segments
- 7.10.5. Product portfolio
- 7.10.6. Business performance
- 7.10.7. Key strategic moves and developments